IP Library Granted Patent US 8,921,103
Granted Patent B2
US 8,921,103 · App. 12/870,128 · Granted Dec 30, 2014

Laminar construct for tissue-engineered dermal equivalent

Inventors: Laura Suggs (Austin, TX); Shanmugasundaram Natesan (San Antonio, TX); Ge Zhang (Hudson, OH); Robert J. Christy (San Antonio, TX); Thomas Walters (Wimberly, TX)
Assignee: Board of Regents, The University of Texas System
C12N5/069C12N2502/1323C12N5/0698C12N2506/1384C12N2502/28C12N2533/56C12N2502/094
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,103
App. No.
12/870,128
Granted
Dec 30, 2014
Kind
B2
Abstract

Compositions and methods for creating a laminar construct for tissue-engineered dermal equivalent are provided. One composition provided herein comprises a hydrogel matrix comprising two or more hydrogels layers and a population of stem cells. Associated methods are also provided.

Claims (10)

1. A method of preparing a dermal equivalent comprising:

providing a synthetic hydrogel matrix comprising at least a first synthetic hydrogel layer and a second synthetic hydrogel layer, wherein the first synthetic hydrogel layer comprises at least one material selected from the group consisting of fibrin, PEGylated fibrin, hyaluronic acid, and any combination thereof and wherein the second synthetic hydrogel layer comprises at least one material selected from the group consisting of collagen I, collagen II, collagen III, collagen IV, collagen V, fibronectin, tenascin, vitronectin, glycosaminoglycans, and any combination thereof;

isolating a population of mesenchymal stem cells from a source; and

differentiating at least one of the mesenchymal stem cells towards a dermal fibroblast and at least one of the mesenchymal stem cells towards a blood vessel cell by introducing the population of mesenchymal stem cells between the first and second synthetic hydrogel layers.

2. The method of claim 1 wherein the source is a patient for whom the dermal equivalent is prepared.

3. The method of claim 1 wherein the mesenchymal stem cells comprise adipose derived stem cells.

4. The method of claim 1 wherein the first synthetic hydrogel layer comprises PEGylated fibrin.

5. The method of claim 1 wherein the mesenchymal stem cells are introduced on microcarriers.

6. The method of claim 1 wherein the second synthetic hydrogel layer comprises collagen I.

7. The method of claim 1 , wherein the synthetic hydrogel matrix is free of soluble growth factors.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2010
From: SUGGS, LAURA; ZHANG, GE
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 025353/0263 →
CONFIRMATORY LICENSE Recorded Sep 29, 2010
From: THE UNIVERSITY OF TEXAS AT AUSTIN
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025060/0218 →
Continuity (2)
Provisional Application 61237868 · Aug 28, 2009
Related Publication 20110053269A1 · Mar 3, 2011